Analysts Set Achieve Life Sciences, Inc. (NASDAQ:ACHV) Price Target at $14.80

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has received a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $14.80.

Several equities research analysts have recently commented on ACHV shares. RODMAN&RENSHAW upgraded shares of Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th. Raymond James initiated coverage on shares of Achieve Life Sciences in a research note on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 price objective for the company. Finally, Rodman & Renshaw assumed coverage on Achieve Life Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $12.00 target price for the company.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ACHV. Barclays PLC boosted its stake in Achieve Life Sciences by 303.1% in the third quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 35,832 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock valued at $3,552,000 after purchasing an additional 48,474 shares during the last quarter. State Street Corp lifted its holdings in shares of Achieve Life Sciences by 6.8% during the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after purchasing an additional 27,419 shares during the last quarter. Verition Fund Management LLC acquired a new stake in shares of Achieve Life Sciences in the 3rd quarter worth $113,000. Finally, MetLife Investment Management LLC grew its stake in Achieve Life Sciences by 65.6% during the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 5,939 shares during the last quarter. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Trading Down 4.1 %

Shares of NASDAQ ACHV opened at $3.55 on Friday. Achieve Life Sciences has a twelve month low of $3.42 and a twelve month high of $5.59. The firm has a market cap of $122.08 million, a PE ratio of -3.14 and a beta of 1.66. The business has a fifty day simple moving average of $4.27 and a two-hundred day simple moving average of $4.52. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same quarter in the previous year, the company posted ($0.34) earnings per share. Analysts expect that Achieve Life Sciences will post -1.17 earnings per share for the current fiscal year.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.